Financials
Financial year 2025
Worth noting
- More debts than assets in the latest financial year.
- A loss two years in a row.
- Little cash and receivables against the short-term debts.
Revenue
€ 2.4 million
▼ 33% vs 2024
Profit
Caution€ -6.5 million
▼ 195% vs 2024
Debts
High€ 20.4 million
▲ 41% vs 2024
Sartorius Xpress Biologics from Herstal, company number BE0550686915, closed financial year 2025 with a result of € -6.5 million after tax. For that financial year Sartorius Xpress Biologics recorded revenue of € 2.4 million and equity of € -9.5 million. Compared with financial year 2024, the result moved from € -2.2 million to € -6.5 million. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on April 13, 2026.
What happened at Sartorius Xpress Biologics?
What happened at Sartorius Xpress Biologics in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Cédric VOLANTI stepped down as director. NBB
- Franck BACKERS stepped down as director. NBB
- New annual accounts for financial year 2025: loss of € 6.5 million. Source: NBB ↗
- Cédric VOLANTI became a director. NBB
- Jonas Skjødt MOLLER stepped down as director. NBB
- Jonas Skjødt MOLLER became a director. NBB
- Franck BACKERS became a director. NBB
- New establishment in Herstal. KBO
In short
From € 59,729 profit in 2021 to € 6.5 million loss in 2025.
Best year ever: 2021, with € 59,729 profit.
On average € 60,300 of value added per employee in 2022.
Pays suppliers within 40 days on average.
A new publication or filing at Sartorius Xpress Biologics? We notify you, reason included.
Follow Sartorius Xpress BiologicsNeed more data?
History
Every financial year, as far back as the National Bank goes.
Buffer
How long does the company survive without income?
Credit limit
Indicative credit limit, computed from the real figures.
Alerts
News about who you follow, reason included.
Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.
Management
The shares are held by XpressBioX SRL (100%). It owns 100% of SARTORIUS ACCESSIA PHARMA itself.
Directors
According to the 2025 annual accounts
since 2025 · until 2031
since 2024 · until 2025
since 2024 · until 2030
Shareholders
100%
Participations
Establishments
Establishment units
Physical locations of this company
Avenue du Parc Industriel 89
4041 Herstal
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.
Website
Technologies
Certifications & Partners
Hosting & Email
Email provider
Microsoft 365
Hosting
BABIEL-NET, DE
Domain
Domain
sartorius.com
Registered
1996-07-15
Registrar
EuroDNS S.A.
Expires
2026-07-14
Website info
Features
Security
Details
- Company number
- 0550.686.915
- VAT number
- BE 0550.686.915
- Registered office
- Avenue du Parc Industriel 89, 4041 Herstal
- Names & denominations
- Sartorius Xpress Biologics
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 16 April 2014
- Peppol
- Active · Active since 25 Jun 2026
- Contact
- sartorius.com
- Activities · NACE
Vervaardiging van farmaceutische grondstoffen
Speur- en ontwikkelingswerk op biotechnologisch gebied
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Overige technische testen en toetsen
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering